Revance Therapeutics, Inc. has initiated the market release of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, aimed at treating cervical dystonia.

Shionogi & Co., Ltd. along with Maze Therapeutics, Inc. have declared a global exclusive licensing deal for MZE001, an innovative therapy aimed at addressing Pompe Disease.

May 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Kite has provided numerous important updates regarding their collaborative project on anitocabtagene autoleucel (anito-cel) for treating multiple myeloma.

5.6-5.12 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

CytomX Therapeutics Reports Promising Early Stage 1a Results for its Solo Therapy CX-904 (EGFRxCD3 PROBODY® T-cell Engager) in Dose Escalation Study.

Freeline Announces Promising Results from Initial Study of FLT201, New Gene Therapy for Gaucher Disease, at ASGCT's 27th Meeting in a Keynote Speech.

TScan Therapeutics has started dosing the first participant in a Phase 1 study to assess TCR-T therapy against solid tumors.

Fate Therapeutics Reports Initial Treatment of a Lupus Patient in its Phase 1 Study for the FT819 CAR T-cell Off-the-shelf Therapy.

Acepodia Reveals Initial Results from Phase 1 Study of ACE1831, the First Anti-CD20 Antibody-Linked Allogeneic Gamma Delta T Cell Treatment for Non-Hodgkin’s Lymphoma.

This acquisition will not only enrich Novartis's research and development pipeline in Radioligand Therapy (RLT) but will also enhance the company’s research foundation and clinical supply capabilities in oncology and RLT platform innovations.

Sobi announced that the European Commission has approved Aspaveli® (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria and haemolytic anaemia.